Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases
Open Access
- 10 August 2023
- journal article
- research article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16 (1) , 1-11
Abstract
Background: The indications for fertility preservation (FP) have expanded. A few patients who underwent gonadotoxic treatment did not have the opportunity to receive FP, leading to concerns that these patients may develop premature ovarian insufficiency. However, the usefulness of FP in women with reduced ovarian reserve has also been questioned. Progestin-primed ovarian stimulation can improve the controlled ovarian stimulation (COS) protocol, but there is limited data on the efficacy of FP with progestin-primed ovarian stimulation. Methods: We conducted a prospective study of 43 women with cancer or autoimmune diseases before and after gonadotoxic treatment at the reproductive unit of Keio University Hospital, counselled between 1 January 2018 and 31 December 2021. After counselling, informed consent was obtained for FP from 43 patients, with those who underwent gonadotoxic treatment of the primary disease being prioritised. Gonadotropin-releasing hormone analogue or progestin was used to suppress luteinising hormone in COS before or after gonadotoxic treatment. The number of cryopreserved mature oocytes was the primary outcome. Results: Forty-three patients and 67 assisted reproductive technology cycles were included in the analysis. The median age at entry was 32 [inter quartile range (IQR), 29–37] years. All patients in the post-gonadotoxic treatment group had their oocytes frozen. Gonadotoxic treatment resulted in fewer oocytes [median 3 (IQR 1–4); pre-gonadotoxic treatment group: five patients, 13 cycles] vs. median 9 (IQR 5–14; pre-gonadotoxic treatment group: 38 patients, 54 cycles; P < 0.001). Although anti-Müllerian hormone levels were lower in the post-gonadotoxic treatment group (n = 5, 13 cycles, median 0.29 (IQR 0.15–1.04) pg/mL) than in the pre-gonadotoxic treatment group (n = 38, 54 cycles, median 1.89 (IQR 1.15–4.08) pg/mL) (P = 0.004), oocyte maturation rates were higher in the post-gonadotoxic treatment group [median 100 (IQR 77.5–100) %] than in the pre-gonadotoxic group [median 90.3 (IQR 75.0–100) %; P = 0.039]. Five patients in the pre-gonadotoxic treatment group had their cryopreserved embryos thawed, of which three had live births. Conclusions: Oocytes obtained for FP from women with cancer or autoimmune disease for FP are of satisfactory quality, regardless of whether they are obtained post-gonadotoxic treatment or COS protocols.Keywords
This publication has 34 references indexed in Scilit:
- Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceHuman Reproduction Update, 2013
- Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort studyHuman Reproduction, 2013
- The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancerEuropean Journal of Cancer, 2012
- How do chemotherapeutic agents damage the ovary?Human Reproduction Update, 2012
- Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)Transplantation and Cellular Therapy, 2011
- Obstetric outcomes following vitrification of in vitro and in vivo matured oocytesFertility and Sterility, 2009
- American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer PatientsJournal of Clinical Oncology, 2006
- Efficacy of in vitro fertilization after chemotherapyFertility and Sterility, 2005
- Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformationsHuman Reproduction, 2001
- Genetic Disease in Offspring of Long-Term Survivors of Childhood and Adolescent CancerThe American Journal of Human Genetics, 1998